Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 5, 2013, Pages 564-572

  Flamm, Robert K ^a   Sader, Helio S ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

AWARE; Ceftaroline; S. aureus; S. pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTAROLINE; CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; PENICILLIN V; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BETA HEMOLYTIC STREPTOCOCCUS; COMMUNITY ACQUIRED RESPIRATORY TRACT INFECTION; DRUG POTENCY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SOUTH AND CENTRAL AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

AWARE; CEFTAROLINE; S. AUREUS; S. PNEUMONIAE;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS;

EID: 84884716440     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2013.02.008     Document Type: Article

References (23)

1. Biek D., Critchley I.A., Riccobene T.A., Thye D.A. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity. J Antimicrob Chemother 2010, 65(Suppl. 4):iv9-iv16.
2. Laudano J.B. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother 2011, 66(Suppl. 3):iii11-iii18.
3. Teflaro Package Insert; 2012. Available at [accessed September 2012]. http://www.frx.com/pi/Teflaro_pi.pdf.
4. European Medicines Assessment Report for Zinforo (ceftaroline fosamil) Procedure No. EMEA/H/C/002252.
5. Jones R.N., Mendes R.E., Sader H.S. Ceftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance study. J Antimicrob Chemother 2010, 65(Suppl. 4):iv17-iv31.
6. Jones R.N., Farrell D.J., Mendes R.E., Sader H.S. Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study. J Antimicrob Chemother 2011, 66(Suppl. 3):iii69-iii80.
7. Corey G.R., Wilcox M., Talbot G.H., et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010, 51:641-650.
8. Corey G.R., Wilcox M.H., Talbot G.H. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65(Suppl. 4):iv41-iv51.
9. Wilcox M.H., Corey G.R., Talbot G.H. CANVAS 2: the second Phase III, randomized double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010, 65(Suppl. 4):iv53-iv65.
10. Critchley I.A., Eckburg P.B., Jandourek A., Biek D., Friedland H.D., Thye D.A. Review of ceftaroline fosamil microbiology: integrated FOCUS studies. J Antimicrob Chemother 2011, 66(Suppl. 3):iii45-iii51.
11. File T.M. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006, 12(Suppl. 3):31-41.
12. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010, 68:334-336.
13. File T.M., Marrie T.J. Burden of community-acquired pneumonia in North American adults. Postgrad Med 2010, 122:130-141.
14. McCaig L.F., McDonald L.C., Mandal S., Jernigan D.B. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis 2006, 12:1715-1723.
15. Moellering R.C. The problem of complicated skin and skin structure infections: the need for new agents. J Antimicrob Chemother 2010, 65(Suppl. 4):iv3-iv8.
16. Drusano G.L. Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity. J Antimicrob Chemother 2010, 65(Suppl. 4):iv33-iv39.
17. Flamm R.K., Sader H.S., Farrell D.J., Jones R.N. Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. Antimicrob Agents Chemother 2012, 56:2933-2940.
18. Farrell D.J., Castanheira M., Mendes R.E., Sader H.S., Jones R.N. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE surveillance program (2008-2010). Clin Infect Dis 2012, 55(Suppl. 3):S206-S214.
19. Sader H.S., Flamm R.K., Farrell D.J., Jones R.N. Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. Clin Infect Dis 2012, 55(Suppl. 3):S181-S186.
20. Pfaller M.A., Farrell D.J., Sader H.S., Jones R.N. AWARE ceftaroline surveillance program (2008-2010); trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. Clin Infect Dis 2012, 55(Suppl. 3):S187-S193.
21. Clinical and Laboratory Standards Institute M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard: ninth edition 2012, CLSI, Wayne, PA, USA.
22. Clinical and Laboratory Standards Institute M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, CLSI, Wayne, PA, USA.
23. Tygacil Package Insert; 2011. Wyeth Pharmaceuticals. Available at [accessed September 2012]. http://www.tygacil.com/.